Clinical Trials
Humanigen Reports Positive Phase 3 Topline Results Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety...
Clinical Trials
Foresee Pharma Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
Foresee Pharmaceuticals Co., Ltd. announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated Acute Respiratory Distress Syndrome (ARDS).
Dr....
News
GSK to support manufacture of Novavax COVID-19 vaccine
GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill...
News
EMA issues advice on the use of Celltrion’s anti-COVID-19 monoclonal antibody treatment regdanvimab for COVID-19 patients in the EU
Celltrion Group announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for the company’s anti-COVID-19 monoclonal antibody treatment candidate, regdanvimab (CT-P59). The CHMP recommends that regdanvimab can be...
Drug Research
University team uses AI to decode asbestos-linked cancer
Researchers at the University of Leicester have used artificial intelligence (AI) to gain new insights into mesothelioma, a cancer caused by breathing asbestos particles that typically occurs in the linings of the lungs or abdomen.
The Leicester Mesothelioma Research Programme...
News
Key milestone in molded glass: SGD Pharma elevates Type I offering with three tailored product and service solutions
SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry and global expert in Type I molded glass, introduces an industry first offering of Type I molded glass vials. These market-driven value propositions represent the latest...
Clinical Trials
CyanVac Selects Exothera for the Development and GMP Mfg anufacturing of its COVID-19 Intranasal Vaccine Candidate for Phase III Clinical Trial is Europe and...
CyanVac LLC, a vaccine company, announced that they have selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), for the development and manufacturing of their COVID-19 intranasal vaccine based on a proprietary parainfluenza virus 5 (PIV5) vector.
Exothera...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read